Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has signed a collaborative agreement with biotechnology firm SomaLogic.

The agreement will see the partners undertake a number of collaborative projects that will employ SomaLogic's proprietary SOMAmer® reagents and SOMAscan® assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions.

We welcome SomaLogic to Oxford, one of Europe's largest centres for biotechnology research. This agreement is a model for how we can bring together the best of industry, academia and the national Health Service to improve healthcare outcomes for patients in the UK and beyond.- Simon Lovestone, Professor of Translational Neuroscience, Department of Psychiatry

In order to maximize the collaborative nature of these projects and accelerate the translation of discoveries into clinical testing, the agreement also includes the build-out of a SOMAscan assay service laboratory at Oxford under the direction of SomaLogic personnel.

Compared to other current proteomic technologies, SomaLogic's platform gives researchers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers.

SomaLogic’s investment in the Oxford University cluster is an excellent example of our unique life sciences offering – world-leading academic researchers working together with the NHS and industry to develop new and innovative tools for better healthcare. - George Freeman, UK Life Sciences minister

The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types, accelerating the discovery of biomarkers across a wide range of diseases and conditions.

Read the full article.


Please follow the link below to read the news on the NIHR BRC website.